Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 8/2014

01.12.2014 | Original Paper

Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis

verfasst von: Todd S. Woodward, Kwanghee Jung, Geoffrey N. Smith, Heungsun Hwang, Alasdair M. Barr, Ric M. Procyshyn, Sean W. Flynn, Mark van der Gaag, William G. Honer

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Refractory psychosis units currently have little information regarding which symptoms profiles should be expected to respond to treatment. In the current study, we provide this information using structural equation modeling of Positive and Negative Syndrome Scale (PANSS) ratings at admission and discharge on a sample of 610 patients admitted to a treatment refractory psychosis program at a Canadian tertiary care unit between 1990 and 2011. The hypothesized five-dimensional structure of the PANSS fit the data well at both admission and discharge, and the latent variable scores are reported as a function of symptom dimension and diagnostic category. The results suggest that, overall, positive symptoms (POS) responded to treatment better than all other symptoms dimensions, but for the schizoaffective and bipolar groups, greater response on POS was observed relative to the schizophrenia and major depression groups. The major depression group showed the most improvement on negative symptoms and emotional distress, and the bipolar group showed the most improvement on disorganization. Schizophrenia was distinct from schizoaffective disorder in showing reduced treatment response on all symptom dimensions. These results can assist refractory psychosis units by providing information on how PANSS symptom dimensions respond to treatment and how this depends on diagnostic category.
Literatur
1.
Zurück zum Zitat Addington D, Bouchard R-H, Goldberg J, Honer WG, Malla AK, Norman RM, Tempier R, Berzins S (2005) Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatr 50:1S–56S Addington D, Bouchard R-H, Goldberg J, Honer WG, Malla AK, Norman RM, Tempier R, Berzins S (2005) Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatr 50:1S–56S
2.
Zurück zum Zitat Agid O, Kapur S, Remington G (2008) Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13:479–495PubMedCrossRef Agid O, Kapur S, Remington G (2008) Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13:479–495PubMedCrossRef
3.
Zurück zum Zitat Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr 162:441–449PubMedCrossRef Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr 162:441–449PubMedCrossRef
4.
Zurück zum Zitat Benabarre A, Vieta E, Colom F, Martínez-Arán A, Reinares M, Gastó C (2001) Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatr 16:167–172CrossRef Benabarre A, Vieta E, Colom F, Martínez-Arán A, Reinares M, Gastó C (2001) Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatr 16:167–172CrossRef
5.
Zurück zum Zitat Cheniaux E, Landeira-Fernandez J, Lessa Telles L, Lessa JL, Dias A, Duncan T, Versiani M (2008) Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 106:209–217PubMedCrossRef Cheniaux E, Landeira-Fernandez J, Lessa Telles L, Lessa JL, Dias A, Duncan T, Versiani M (2008) Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 106:209–217PubMedCrossRef
6.
Zurück zum Zitat Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatr 61:329–334CrossRef Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatr 61:329–334CrossRef
7.
Zurück zum Zitat Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, McTigue O, Kinsella A, Waddington JL, Larkin C, O’Callaghan E (2009) Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatr 194:18–24CrossRef Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, McTigue O, Kinsella A, Waddington JL, Larkin C, O’Callaghan E (2009) Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatr 194:18–24CrossRef
8.
Zurück zum Zitat Daniels BA, Kirkby KC, Hay DA, Mowry BJ, Jones IH (1998) Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 32:280CrossRef Daniels BA, Kirkby KC, Hay DA, Mowry BJ, Jones IH (1998) Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 32:280CrossRef
9.
Zurück zum Zitat Efron B (1981) Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika 68:589–599CrossRef Efron B (1981) Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika 68:589–599CrossRef
10.
Zurück zum Zitat Emsley R, Rabinowitz J, Torreman M (2003) The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 61:47–57PubMedCrossRef Emsley R, Rabinowitz J, Torreman M (2003) The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res 61:47–57PubMedCrossRef
11.
Zurück zum Zitat Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB, Mechelli A, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SC, McGuire P (2011) Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. Schizophr Bull 37:189–198PubMedCentralPubMedCrossRef Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB, Mechelli A, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SC, McGuire P (2011) Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. Schizophr Bull 37:189–198PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Guy W (ed) (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, Rockville, pp 218–222 Guy W (ed) (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, Rockville, pp 218–222
13.
Zurück zum Zitat Hwang H, Malhotra NK, Kim Y, Tomiuk MA, Hong S (2010) A comparative study on parameter recovery of three approaches to structural equation modeling. J Mark Res 47:699–712CrossRef Hwang H, Malhotra NK, Kim Y, Tomiuk MA, Hong S (2010) A comparative study on parameter recovery of three approaches to structural equation modeling. J Mark Res 47:699–712CrossRef
14.
Zurück zum Zitat Hwang H, Takane Y (2004) Generalized structured component analysis. Psychometrika 69:81–99CrossRef Hwang H, Takane Y (2004) Generalized structured component analysis. Psychometrika 69:81–99CrossRef
15.
Zurück zum Zitat Johnstone E, Frith CD, Crow TJ, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 311:848–851CrossRef Johnstone E, Frith CD, Crow TJ, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 311:848–851CrossRef
16.
Zurück zum Zitat Jöreskog KG (1970) A general method for analysis of covariance structures. Biometrika 57:239–251CrossRef Jöreskog KG (1970) A general method for analysis of covariance structures. Biometrika 57:239–251CrossRef
17.
Zurück zum Zitat Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13–23PubMedCrossRef Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13–23PubMedCrossRef
18.
Zurück zum Zitat Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 13:261–276PubMedCrossRef Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 13:261–276PubMedCrossRef
19.
Zurück zum Zitat Kay SR, Opler LA, Lindenmayer J-P (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110PubMedCrossRef Kay SR, Opler LA, Lindenmayer J-P (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110PubMedCrossRef
20.
Zurück zum Zitat Kay SR, Opler LA, Lindenmayer JP (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and Standardisation. Br J Psychiatry 155:59–65 Kay SR, Opler LA, Lindenmayer JP (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and Standardisation. Br J Psychiatry 155:59–65
21.
Zurück zum Zitat Kriston L, Härter M, Scholl I (2012) A latent variable framework for modeling dyadic measures in research on shared decision-making. Z Evid Fortbild Qual Gesundh wesen 106:253–263CrossRef Kriston L, Härter M, Scholl I (2012) A latent variable framework for modeling dyadic measures in research on shared decision-making. Z Evid Fortbild Qual Gesundh wesen 106:253–263CrossRef
22.
Zurück zum Zitat Lancon C, Auquier P, Nayt G, Reine G (2000) Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 42:231–239PubMedCrossRef Lancon C, Auquier P, Nayt G, Reine G (2000) Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 42:231–239PubMedCrossRef
23.
Zurück zum Zitat Leucht S, Kane J, Etschel E, Kissling W, Hamann J, Engel RR (2006) Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31:2318–2325PubMedCrossRef Leucht S, Kane J, Etschel E, Kissling W, Hamann J, Engel RR (2006) Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31:2318–2325PubMedCrossRef
24.
Zurück zum Zitat Levine SZ, Rabinowitz J (2007) Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J Clin Psychopharmacol 27:431–436PubMedCrossRef Levine SZ, Rabinowitz J (2007) Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J Clin Psychopharmacol 27:431–436PubMedCrossRef
25.
Zurück zum Zitat Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S (2008) Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 98:318–322PubMedCrossRef Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S (2008) Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 98:318–322PubMedCrossRef
26.
Zurück zum Zitat Liddle PF, Ngan ETN, Duffield G, Kho K, Warren AJ (2002) The signs and symptoms of psychotic illness: a rating scale. Br J Psychiatry 180:45–50PubMedCrossRef Liddle PF, Ngan ETN, Duffield G, Kho K, Warren AJ (2002) The signs and symptoms of psychotic illness: a rating scale. Br J Psychiatry 180:45–50PubMedCrossRef
27.
28.
Zurück zum Zitat Mass R, Schoemig T, Hitschfeld K, Wall E, Haasen C (2000) Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale. Schizophr Bull 26:167–177PubMedCrossRef Mass R, Schoemig T, Hitschfeld K, Wall E, Haasen C (2000) Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale. Schizophr Bull 26:167–177PubMedCrossRef
29.
Zurück zum Zitat May P, Dencker S, Hubbard J, Midha K, Liberman R (1988) A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker S, Kulhanek F (eds) Treatment resistance in schizophrenia. Vieweg, Braunschweig, Weisbaden, pp 22–33 May P, Dencker S, Hubbard J, Midha K, Liberman R (1988) A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker S, Kulhanek F (eds) Treatment resistance in schizophrenia. Vieweg, Braunschweig, Weisbaden, pp 22–33
30.
Zurück zum Zitat McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O’Brien S (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411–414PubMed McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O’Brien S (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411–414PubMed
31.
Zurück zum Zitat Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E (2011) What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharm 21:680–690CrossRef Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E (2011) What we know and what we don’t know about the treatment of schizoaffective disorder. Eur Neuropsychopharm 21:680–690CrossRef
32.
Zurück zum Zitat Reichenberg A, Rieckmann N, Harvey PD (2005) Stability in schizophrenia symptoms over time: findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study. J Abnorm Psychol 114:363–372PubMedCrossRef Reichenberg A, Rieckmann N, Harvey PD (2005) Stability in schizophrenia symptoms over time: findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study. J Abnorm Psychol 114:363–372PubMedCrossRef
33.
Zurück zum Zitat Schottle D, Schimmelmann BG, Conus P, Cotton SM, Michel C, McGorry PD, Karow A, Naber D, Lambert M (2012) Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophr Res 140:31–36PubMedCrossRef Schottle D, Schimmelmann BG, Conus P, Cotton SM, Michel C, McGorry PD, Karow A, Naber D, Lambert M (2012) Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophr Res 140:31–36PubMedCrossRef
34.
Zurück zum Zitat Smith GN, MacEwan GW, Ancill RJ, Honer WG, Ehmann TS (1992) Diagnostic confusion in treatment-refractory psychotic patients. J Clin Psychiatry 53:197–200PubMed Smith GN, MacEwan GW, Ancill RJ, Honer WG, Ehmann TS (1992) Diagnostic confusion in treatment-refractory psychotic patients. J Clin Psychiatry 53:197–200PubMed
35.
Zurück zum Zitat Souza JS, Kayo M, Tassell I, Martins CB, Elkis H (2013) Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 18:82–89PubMedCrossRef Souza JS, Kayo M, Tassell I, Martins CB, Elkis H (2013) Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 18:82–89PubMedCrossRef
36.
Zurück zum Zitat Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC (2011) Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry 199:275–280PubMedCrossRef Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC (2011) Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry 199:275–280PubMedCrossRef
37.
Zurück zum Zitat Tenenhaus M (2008) Component-based Structural Equation Modelling. Total Qual Manag Bus 19:871–886CrossRef Tenenhaus M (2008) Component-based Structural Equation Modelling. Total Qual Manag Bus 19:871–886CrossRef
38.
Zurück zum Zitat van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF (2009) A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 107:13–21PubMedCentralPubMedCrossRef van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF (2009) A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 107:13–21PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D (2006) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 85:280–287PubMedCrossRef van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D (2006) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 85:280–287PubMedCrossRef
40.
Zurück zum Zitat White L, Harvey PD, Opler L, Lindenmayer JP (1997) Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30:263–274PubMedCrossRef White L, Harvey PD, Opler L, Lindenmayer JP (1997) Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30:263–274PubMedCrossRef
Metadaten
Titel
Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis
verfasst von
Todd S. Woodward
Kwanghee Jung
Geoffrey N. Smith
Heungsun Hwang
Alasdair M. Barr
Ric M. Procyshyn
Sean W. Flynn
Mark van der Gaag
William G. Honer
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 8/2014
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-013-0460-x

Weitere Artikel der Ausgabe 8/2014

European Archives of Psychiatry and Clinical Neuroscience 8/2014 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.